<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39339209</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1173</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics16091173</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">Dendrimer-based astodrimer sodium nasal spray was assessed for its ability to reduce SARS-CoV-2 load in outpatients with COVID-19, which remains a severe illness for vulnerable groups.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a randomised, double-blind, placebo-controlled clinical investigation evaluating the efficacy of astodrimer nasal spray in reducing SARS-CoV-2 viral burden in the nasopharynx of outpatients with COVID-19. Non-hospitalised adults with SARS-CoV-2 infection were randomised 1:1 to astodrimer or placebo four times daily from Day 1 to Day 7. Nasopharyngeal swabs for SARS-CoV-2 load determination were self-obtained daily from Day 1 to Day 8. The primary endpoint was an area under the curve of SARS-CoV-2 RNA copies/mL through Day 8 (vAUC<sub>d1-8</sub>). The primary analysis population was the modified intent-to-treat population (mITT: all randomised participants exposed to the study treatment who had at least one post-baseline viral load determination). Safety analyses included all randomised participants exposed to the study treatment.</AbstractText><AbstractText Label="STUDY REGISTRATION" NlmCategory="BACKGROUND">ISRCTN70449927; Results: 231 participants were recruited between 9 January and 20 September 2023. The safety population comprised 109 and 113 participants randomised to astodrimer and placebo, respectively, with 96 and 101 participants in the mITT. Astodrimer sodium nasal spray reduced the SARS-CoV-2 burden (vAUC<sub>d1-8</sub>) vs. placebo in non-hospitalised COVID-19 patients aged 16 years and over (-1.2 log<sub>10</sub> copies/mL × Day). The reduction in SARS-CoV-2 load was statistically significant in those aged 45 years and older (-3.7, <i>p</i> = 0.017) and the effect increased in older age groups, including in those aged 65 years and older (-7.3, <i>p</i> = 0.005). Astodrimer sodium nasal spray increased the rate of viral clearance and helped alleviate some COVID-19 symptoms, especially loss of sense of smell. Overall, 31 participants (14%) had ≥1 adverse event (AE). Four AEs were deemed possibly related to treatment. Most AEs were of mild severity and occurred at similar rates in both treatment arms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Astodrimer nasal spray reduces viral burden and accelerates viral clearance, especially in older populations, and is well tolerated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winchester</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Frimley Health National Health Service Foundation Trust, Camberley GU16 7UJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellarnau</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Starpharma Pty Ltd., Abbotsford, VIC 3067, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jabbar</LastName><ForeName>Kashif</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Ashford and St. Peter's Hospitals National Health Service Foundation Trust, Chertsey KT16 0PZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadir</LastName><ForeName>Meera</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ashford and St. Peter's Hospitals National Health Service Foundation Trust, Chertsey KT16 0PZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranasinghe</LastName><ForeName>Kapila</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Ashford and St. Peter's Hospitals National Health Service Foundation Trust, Chertsey KT16 0PZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masramon</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Servicio de Asesoría a la Investigación y Logística (SAIL), 08027 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinghorn</LastName><ForeName>George R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Royal Hallamshire Hospital, University of Sheffield, Western Bank, Sheffield S10 2TN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2856-6180</Identifier><AffiliationInfo><Affiliation>Ashford and St. Peter's Hospitals National Health Service Foundation Trust, Chertsey KT16 0PZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal Holloway, University of London, Egham TW20 0EX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paull</LastName><ForeName>Jeremy R A</ForeName><Initials>JRA</Initials><Identifier Source="ORCID">0000-0002-9981-421X</Identifier><AffiliationInfo><Affiliation>Starpharma Pty Ltd., Abbotsford, VIC 3067, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Not applicable</GrantID><Agency>Starpharma Pty Ltd</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SPL7013</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">astodrimer</Keyword><Keyword MajorTopicYN="N">dendrimer</Keyword><Keyword MajorTopicYN="N">intranasal spray</Keyword></KeywordList><CoiStatement>J.R.A.P. is a paid employee and equity holder of Starpharma Pty Ltd. A.C., G.R.K. and S.W. are paid consultants to Starpharma Pty Ltd. I.J. is the founder and CEO of Metanoic Health Ltd., which received payment from Starpharma Pty Ltd. for the implementation and management of the investigation. S.W. is a paid consultant to Metanoic Health Ltd. X.M. is co-founder and paid employee of Servicio de Asesoría a la Investigación y Logística (SAIL), which received payment from Starpharma Pty Ltd. for providing statistical services for the investigation. K.J., M.N. and K.R. have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339209</ArticleId><ArticleId IdType="pmc">PMC11435287</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics16091173</ArticleId><ArticleId IdType="pii">pharmaceutics16091173</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Little P., Read R.C., Amlôt R., Chadborn T., Rice C., Bostock J., Yardley L. Reducing Risks from Coronavirus Transmission in the Home-the Role of Viral Load. BMJ. 2020;369:m1728. doi: 10.1136/bmj.m1728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1728</ArticleId><ArticleId IdType="pubmed">32376669</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai M., Iwatsuki-Horimoto K., Hatta M., Loeber S., Halfmann P.J., Nakajima N., Watanabe T., Ujie M., Takahashi K., Ito M., et al. Syrian Hamsters as a Small Animal Model for SARS-CoV-2 Infection and Countermeasure Development. Proc. Natl. Acad. Sci. USA. 2020;117:16587–16595. doi: 10.1073/pnas.2009799117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2009799117</ArticleId><ArticleId IdType="pmc">PMC7368255</ArticleId><ArticleId IdType="pubmed">32571934</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabisch P.A., Biryukov J., Beck K., Boydston J.A., Sanjak J.S., Herzog A., Green B., Williams G., Yeager J., Bohannon J.K., et al. Seroconversion and Fever Are Dose-Dependent in a Nonhuman Primate Model of Inhalational COVID-19. PLoS Pathog. 2021;17:e1009865. doi: 10.1371/journal.ppat.1009865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009865</ArticleId><ArticleId IdType="pmc">PMC8412324</ArticleId><ArticleId IdType="pubmed">34424943</ArticleId></ArticleIdList></Reference><Reference><Citation>Memoli M.J., Czajkowski L., Reed S., Athota R., Bristol T., Proudfoot K., Fargis S., Stein M., Dunfee R.L., Shaw P.A., et al. Validation of the Wild-Type Influenza A Human Challenge Model H1N1pdMIST: An A(H1N1)Pdm09 Dose-Finding Investigational New Drug Study. Clin. Infect. Dis. 2015;60:693–702. doi: 10.1093/cid/ciu924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu924</ArticleId><ArticleId IdType="pmc">PMC4342672</ArticleId><ArticleId IdType="pubmed">25416753</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Yan L.-M., Wan L., Xiang T.-X., Le A., Liu J.-M., Peiris M., Poon L.L.M., Zhang W. Viral Dynamics in Mild and Severe Cases of COVID-19. Lancet Infect. Dis. 2020;20:656–657. doi: 10.1016/S1473-3099(20)30232-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30232-2</ArticleId><ArticleId IdType="pmc">PMC7158902</ArticleId><ArticleId IdType="pubmed">32199493</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajnzylber J., Regan J., Coxen K., Corry H., Wong C., Rosenthal A., Worrall D., Giguel F., Piechocka-Trocha A., Atyeo C., et al. SARS-CoV-2 Viral Load Is Associated with Increased Disease Severity and Mortality. Nat. Commun. 2020;11:5493. doi: 10.1038/s41467-020-19057-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19057-5</ArticleId><ArticleId IdType="pmc">PMC7603483</ArticleId><ArticleId IdType="pubmed">33127906</ArticleId></ArticleIdList></Reference><Reference><Citation>Maltezou H.C., Raftopoulos V., Vorou R., Papadima K., Mellou K., Spanakis N., Kossyvakis A., Gioula G., Exindari M., Froukala E., et al. Association Between Upper Respiratory Tract Viral Load, Comorbidities, Disease Severity, and Outcome of Patients with SARS-CoV-2 Infection. J. Infect. Dis. 2021;223:1132–1138. doi: 10.1093/infdis/jiaa804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa804</ArticleId><ArticleId IdType="pmc">PMC7798974</ArticleId><ArticleId IdType="pubmed">33388780</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva S.J.R., de Lima S.C., da Silva R.C., Kohl A., Pena L. Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. Front. Med. 2021;8:836826. doi: 10.3389/fmed.2021.836826.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.836826</ArticleId><ArticleId IdType="pmc">PMC8841511</ArticleId><ArticleId IdType="pubmed">35174189</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasuji H., Takegoshi Y., Kaneda M., Ueno A., Miyajima Y., Kawago K., Fukui Y., Yoshida Y., Kimura M., Yamada H., et al. Transmissibility of COVID-19 Depends on the Viral Load around Onset in Adult and Symptomatic Patients. PLoS ONE. 2020;15:e0243597. doi: 10.1371/journal.pone.0243597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243597</ArticleId><ArticleId IdType="pmc">PMC7725311</ArticleId><ArticleId IdType="pubmed">33296437</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz E.A., Scott J., Richterman A., Male V., Cevik M. Clinical Course and Management of COVID-19 in the Era of Widespread Population Immunity. Nat. Rev. Microbiol. 2024;22:75–88. doi: 10.1038/s41579-023-01001-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-01001-1</ArticleId><ArticleId IdType="pubmed">38114838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis D. Is the Coronavirus Airborne? Experts Can’t Agree. Nature. 2020;580:175. doi: 10.1038/d41586-020-00974-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-00974-w</ArticleId><ArticleId IdType="pubmed">32242113</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang S., Mao Y., Jones R.M., Tan Q., Ji J.S., Li N., Shen J., Lv Y., Pan L., Ding P., et al. Aerosol Transmission of SARS-CoV-2? Evidence, Prevention and Control. Environ. Int. 2020;144:106039. doi: 10.1016/j.envint.2020.106039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envint.2020.106039</ArticleId><ArticleId IdType="pmc">PMC7413047</ArticleId><ArticleId IdType="pubmed">32822927</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J., Grantham M., Pantelic J., Bueno de Mesquita P.J., Albert B., Liu F., Ehrman S., Milton D.K. EMIT Consortium Infectious Virus in Exhaled Breath of Symptomatic Seasonal Influenza Cases from a College Community. Proc. Natl. Acad. Sci. USA. 2018;115:1081–1086. doi: 10.1073/pnas.1716561115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1716561115</ArticleId><ArticleId IdType="pmc">PMC5798362</ArticleId><ArticleId IdType="pubmed">29348203</ArticleId></ArticleIdList></Reference><Reference><Citation>Paull J.R.A., Heery G.P., Bobardt M.D., Castellarnau A., Luscombe C.A., Fairley J.K., Gallay P.A. Virucidal and Antiviral Activity of Astodrimer Sodium against SARS-CoV-2 in Vitro. Antiviral Res. 2021;191:105089. doi: 10.1016/j.antiviral.2021.105089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2021.105089</ArticleId><ArticleId IdType="pmc">PMC8126375</ArticleId><ArticleId IdType="pubmed">34010661</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallay P.A., Luscombe C.A., Stauffer W., Bobardt M.D., Heery G.P., Castellarnau A., Seta A., Paull J.R.A. Effects of Astodrimer Sodium against SARS-CoV-2 Variants (α, β, γ, δ, κ) in Vitro [CROI Abstract 478]. Special Issue: Abstracts from the Virtual 2022 Conference on Retroviruses and Opportunistic Infections. Top. Antivir. Med. 2022;30:182.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Paull J.R.A., Luscombe C.A., Castellarnau A., Heery G.P., Bobardt M.D., Gallay P.A. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice. Viruses. 2021;13:1656. doi: 10.3390/v13081656.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13081656</ArticleId><ArticleId IdType="pmc">PMC8402925</ArticleId><ArticleId IdType="pubmed">34452519</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellarnau A., Heery G.P., Seta A., Luscombe C.A., Kinghorn G.R., Button P., McCloud P., Paull J.R.A. Astodrimer Sodium Antiviral Nasal Spray for Reducing Respiratory Infections Is Safe and Well Tolerated in a Randomized Controlled Trial. Sci. Rep. 2022;12:10210. doi: 10.1038/s41598-022-14601-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-14601-3</ArticleId><ArticleId IdType="pmc">PMC9204674</ArticleId><ArticleId IdType="pubmed">35715644</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection A Minimal Common Outcome Measure Set for COVID-19 Clinical Research. Lancet Infect. Dis. 2020;20:e192–e197. doi: 10.1016/S1473-3099(20)30483-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers J.H., Guerrero M.L., Leidy N.K., Fairchok M.P., Rosenberg A., Hernández A., Stringer S., Schofield C., Rodríguez-Zulueta P., Kim K., et al. Development of the Flu-PRO: A Patient-Reported Outcome (PRO) Instrument to Evaluate Symptoms of Influenza. BMC Infect. Dis. 2016;16:1. doi: 10.1186/s12879-015-1330-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1330-0</ArticleId><ArticleId IdType="pmc">PMC4700740</ArticleId><ArticleId IdType="pubmed">26729246</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers J.H., Bacci E.D., Guerrero M.L., Leidy N.K., Stringer S., Kim K., Memoli M.J., Han A., Fairchok M.P., Chen W.-J., et al. Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients. Value Health. 2018;21:210–218. doi: 10.1016/j.jval.2017.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2017.04.014</ArticleId><ArticleId IdType="pmc">PMC5831548</ArticleId><ArticleId IdType="pubmed">29477403</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadras O., Afsahi A.M., Pashaei Z., Mojdeganlou H., Karimi A., Habibi P., Barzegary A., Fakhfouri A., Mirzapour P., Janfaza N., et al. The Relationship between COVID-19 Viral Load and Disease Severity: A Systematic Review. Immun. Inflamm. Dis. 2022;10:e580. doi: 10.1002/iid3.580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.580</ArticleId><ArticleId IdType="pmc">PMC8926507</ArticleId><ArticleId IdType="pubmed">34904379</ArticleId></ArticleIdList></Reference><Reference><Citation>Winchester S., John S., Jabbar K., John I. Clinical Efficacy of Nitric Oxide Nasal Spray (NONS) for the Treatment of Mild COVID-19 Infection. J. Infect. 2021;83:237–279. doi: 10.1016/j.jinf.2021.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.05.009</ArticleId><ArticleId IdType="pmc">PMC8117664</ArticleId><ArticleId IdType="pubmed">33992687</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin S., Benk I.G., Geckil A.A. May Viral Load Detected in Saliva in the Early Stages of Infection Be a Prognostic Indicator in COVID-19 Patients? J. Virol. Methods. 2021;294:114198. doi: 10.1016/j.jviromet.2021.114198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114198</ArticleId><ArticleId IdType="pmc">PMC8142821</ArticleId><ArticleId IdType="pubmed">34044003</ArticleId></ArticleIdList></Reference><Reference><Citation>Vegvari C., Hadjichrysanthou C., Cauët E., Lawrence E., Cori A., de Wolf F., Anderson R.M. How Can Viral Dynamics Models Inform Endpoint Measures in Clinical Trials of Therapies for Acute Viral Infections? PLoS ONE. 2016;11:e0158237. doi: 10.1371/journal.pone.0158237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0158237</ArticleId><ArticleId IdType="pmc">PMC4930163</ArticleId><ArticleId IdType="pubmed">27367230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz J.G., Andrew M.K. COVID-19 Vaccination and Hybrid Immunity in Older Adults. Lancet Healthy Longev. 2023;4:e364–e365. doi: 10.1016/S2666-7568(23)00112-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(23)00112-5</ArticleId><ArticleId IdType="pubmed">37459880</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar-Debbiny R., Gronich N., Weber G., Khoury J., Amar M., Stein N., Goldstein L.H., Saliba W. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis. 2023;76:e342–e349. doi: 10.1093/cid/ciac443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac443</ArticleId><ArticleId IdType="pmc">PMC9214014</ArticleId><ArticleId IdType="pubmed">35653428</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J., Radke J., Dittmayer C., Franz J., Thomas C., Mothes R., Laue M., Schneider J., Brünink S., Greuel S., et al. Olfactory Transmucosal SARS-CoV-2 Invasion as a Port of Central Nervous System Entry in Individuals with COVID-19. Nat. Neurosci. 2021;24:168–175. doi: 10.1038/s41593-020-00758-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M., Canoll P.D., Klein R.S. How COVID-19 Affects the Brain. JAMA Psychiatry. 2021;78:682–683. doi: 10.1001/jamapsychiatry.2021.0500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2021.0500</ArticleId><ArticleId IdType="pmc">PMC9894299</ArticleId><ArticleId IdType="pubmed">33769431</ArticleId></ArticleIdList></Reference><Reference><Citation>Anwar M.M., Badawi A.M., Eltablawy N.A. Can the Coronavirus Infection Penetrates the Brain Resulting in Sudden Anosmia Followed by Severe Neurological Disorders? eNeurologicalSci. 2020;21:100290. doi: 10.1016/j.ensci.2020.100290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2020.100290</ArticleId><ArticleId IdType="pmc">PMC7657010</ArticleId><ArticleId IdType="pubmed">33200104</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilarello B.J., Jacobson P.T., Tervo J.P., Waring N.A., Gudis D.A., Goldberg T.E., Devanand D.P., Overdevest J.B. Olfaction and Neurocognition after COVID-19: A Scoping Review. Front. Neurosci. 2023;17:1198267. doi: 10.3389/fnins.2023.1198267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2023.1198267</ArticleId><ArticleId IdType="pmc">PMC10339825</ArticleId><ArticleId IdType="pubmed">37457004</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>